Abstral is a formulation of
fentanyl citrate available as a
sublingual tablet. It dissolves quickly and is absorbed through the
sublingual mucosa to provide rapid
analgesia. In the UK, Abstral is licensed for the treatment of breakthrough
cancer pain (BTcP) in patients with otherwise stable, baseline persistent pain that is managed with conventional
opioids.